Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Immunotherapy
; 14(6): 409-418, 2022 04.
Article
em En
| MEDLINE
| ID: mdl-35232282
A new type of cancer treatment termed 'immunotherapy' alters a patient's own immune system to attack the cancer cells. However, cemiplimab and similar medications can sometimes inadvertently injure the liver or other organs due to off-target activation of the immune system. This study describes the frequency and outcomes of liver injury observed in 39 patients with advanced skin cancer who were treated with cemiplimab at a single center. The authors found that 10% of patients developed liver injury, but only half of the cases were due to immune-mediated liver injury. The liver injury in these four patients was generally mild and self-limited. This study suggests that cemiplimab may be a preferred immunotherapy agent for patients with underlying liver disease due to its generally favorable side-effect profile, but further studies are needed.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Carcinoma de Células Escamosas
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos